These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 11062371

  • 41. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):32-43. PubMed ID: 15629591
    [Abstract] [Full Text] [Related]

  • 42. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
    Arcangeli G, Strigari L, Arcangeli S, Petrongari MG, Saracino B, Gomellini S, Papalia R, Simone G, De Carli P, Gallucci M.
    Int J Radiat Oncol Biol Phys; 2009 Nov 15; 75(4):975-82. PubMed ID: 19395188
    [Abstract] [Full Text] [Related]

  • 43. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.
    J Urol; 2007 Nov 15; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [Abstract] [Full Text] [Related]

  • 44. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF, Regan MM, Olumi AF, DeWolf WC.
    J Urol; 2004 Apr 15; 171(4):1492-9. PubMed ID: 15017206
    [Abstract] [Full Text] [Related]

  • 45. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.
    Eur Urol; 2007 Apr 15; 51(4):931-9. PubMed ID: 16935413
    [Abstract] [Full Text] [Related]

  • 46. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels.
    Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC, Trock B, Amling CL.
    Cancer; 2004 Aug 15; 101(4):748-53. PubMed ID: 15305405
    [Abstract] [Full Text] [Related]

  • 47. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H.
    BJU Int; 2005 Apr 15; 95(6):751-6. PubMed ID: 15794776
    [Abstract] [Full Text] [Related]

  • 48. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.
    Urology; 2005 Jan 15; 65(1):95-100. PubMed ID: 15667872
    [Abstract] [Full Text] [Related]

  • 49. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N, Saito S, Ishidoya S, Ito A, Saito H, Kato M, Arai Y.
    Int J Urol; 2009 Sep 15; 16(9):733-8. PubMed ID: 19674167
    [Abstract] [Full Text] [Related]

  • 50. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.
    J Urol; 2001 Dec 15; 166(6):2193-7. PubMed ID: 11696734
    [Abstract] [Full Text] [Related]

  • 51. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
    D'Amico AV, Chen MH, Roehl KA, Catalona WJ.
    J Clin Oncol; 2005 Aug 01; 23(22):4975-9. PubMed ID: 16051949
    [Abstract] [Full Text] [Related]

  • 52. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M, Stamey TA, McNeal JE, Yemoto CM.
    J Urol; 2001 Jul 01; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [Abstract] [Full Text] [Related]

  • 53. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
    Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR.
    J Urol; 2001 Jul 01; 166(1):111-5. PubMed ID: 11435834
    [Abstract] [Full Text] [Related]

  • 54. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
    Guzzo TJ, Levin BM, Lee R, Guo M, Chen Z, Whittington R, Tomaszewski J, Malkowicz SB.
    Urology; 2008 Apr 01; 71(4):723-7. PubMed ID: 18387401
    [Abstract] [Full Text] [Related]

  • 55. Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.
    Igdem S, Abacioglu U, Cetin I, Alco G, Akgun Z, Sengoz M, Bekiroglu N, Turkan S, Okkan S.
    J BUON; 2009 Apr 01; 14(4):629-34. PubMed ID: 20148454
    [Abstract] [Full Text] [Related]

  • 56. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer.
    Roach M, Chen A, Song J, Diaz A, Presti J, Carroll P.
    Semin Urol Oncol; 2000 May 01; 18(2):108-14. PubMed ID: 10875450
    [Abstract] [Full Text] [Related]

  • 57. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors.
    D'Amico AV, Schultz D, Schneider L, Hurwitz M, Kantoff PW, Richie JP.
    J Urol; 2000 Jun 01; 163(6):1797-801. PubMed ID: 10799185
    [Abstract] [Full Text] [Related]

  • 58. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy.
    D'Amico AV, Desjardin A, Chung A, Chen MH, Schultz D, Whittington R, Malkowicz SB, Wein A, Tomaszewski JE, Renshaw AA, Loughlin K, Richie JP.
    Cancer; 1998 May 15; 82(10):1887-96. PubMed ID: 9587121
    [Abstract] [Full Text] [Related]

  • 59. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD, Goldberg JD, Hochman T, Lepor H.
    Eur Urol; 2011 Sep 15; 60(3):548-53. PubMed ID: 21652145
    [Abstract] [Full Text] [Related]

  • 60. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
    D'Amico AV, Chen MH, Roehl KA, Catalona WJ.
    N Engl J Med; 2004 Jul 08; 351(2):125-35. PubMed ID: 15247353
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.